FAS and neoplasm: These results suggest that treatment with decitabine not only increases the expression of an immunogenic CTA, but can also re-establish functionality of the apoptotic signaling system within tumor cells and sensitize these cells to immune-mediated cell death via the Fas/Fas Ligand pathway.